Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 6, 2005, reporting an event that occurred on December 31, 2004. The company announced the execution of a First Amendment to its Collaboration Agreement with Aventis Pharmaceuticals, Inc., originally dated September 5, 2003. This amendment specifically modified the requirements for a previously defined $25 million milestone payment. Regeneron has successfully met these revised requirements and, as a result, earned the $25 million milestone payment in December 2004. No other terms of the original Collaboration Agreement were altered.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. entered into a First Amendment to its Collaboration Agreement with Aventis Pharmaceuticals, Inc.
- 2The amendment was dated December 31, 2004.
- 3The primary purpose of the amendment was to alter the requirements for a $25 million milestone payment.
- 4Regeneron has successfully met the amended requirements for this milestone.
- 5The company has earned and received the $25 million milestone payment in December 2004.
- 6No other terms of the original September 5, 2003 Collaboration Agreement were changed.
Frequently Asked Questions
The key financial event is Regeneron Pharmaceuticals, Inc. earning and receiving a $25 million milestone payment from Aventis Pharmaceuticals, Inc. due to meeting amended collaboration terms.
The amendment specifically adjusted the conditions that Regeneron needed to fulfill to receive a $25 million milestone payment. All other aspects of the original agreement remain unchanged.
Regeneron met the amended requirements and earned the $25 million milestone payment in December 2004.
No, the filing explicitly states that no other changes were made to the terms of the original Collaboration Agreement dated September 5, 2003.